Oxaliplatin: Platinum-Based Chemotherapeutic Agent—Comprehensive Fact Dossier

Executive Summary: Oxaliplatin (CAS 61825-94-3) is a third-generation platinum-based chemotherapeutic agent with a well-characterized mechanism of inducing apoptosis via DNA adducts and secondary DNA damage [product_spec, APExBIO]. Its cytotoxicity spans melanoma, ovarian carcinoma, bladder, colon, and glioblastoma cell lines, with IC₅₀ values in the submicromolar to micromolar range [product_spec, APExBIO]. Benchmark protocols in metastatic colorectal cancer therapy use Oxaliplatin in combination with fluorouracil and folinic acid, demonstrating significant tumor volume reduction in xenograft models [paper, Shapira-Netanelov et al., 2025]. Recent assembloid models reveal the impact of tumor–stroma interactions on Oxaliplatin’s efficacy and resistance [paper, Cancers 2025]. The compound is supplied by APExBIO as SKU A8648, with validated storage and preparation protocols for lab workflows [product_spec, APExBIO].

Biological Rationale

Oxaliplatin’s primary clinical and research indication is its role as a platinum-based chemotherapeutic agent for cancer chemotherapy, especially in metastatic colorectal cancer therapy [product_spec, APExBIO]. Its broad cytotoxic spectrum covers colon, ovarian, melanoma, bladder, and glioblastoma cell lines [product_spec, APExBIO]. The rationale rests on its ability to form DNA adducts that disrupt replication and induce apoptosis, making it a tool in DNA damage and repair studies [product_spec]. New assembloid models incorporating stromal subpopulations increase the physiological relevance of Oxaliplatin response assays, capturing microenvironmental factors that influence efficacy and resistance [paper, Cancers 2025].

Mechanism of Action of Oxaliplatin

Oxaliplatin exerts cytotoxicity through the formation of DNA adducts, leading to DNA crosslinks that block DNA synthesis and trigger apoptosis via p53-dependent and independent pathways [product_spec, APExBIO]. Secondary DNA damage and interference with DNA repair enzymes amplify its apoptotic effect [internal, CRISPRCASY]. The platinum moiety facilitates covalent binding to guanine residues, resulting in intra- and inter-strand crosslinks. This mechanism has been validated in both 2D and 3D tumor models, including advanced organoid and assembloid systems that recapitulate tumor–stroma complexity [paper, Cancers 2025].

Evidence & Benchmarks

• Oxaliplatin exhibits IC₅₀ values ranging from submicromolar to micromolar concentrations in cancer cell lines under standard culture conditions (e.g., 0.1–10 μM, 48–72h exposure) [product_spec, APExBIO].
• In xenograft mouse models, intraperitoneal or intravenous administration of 5–10 mg/kg Oxaliplatin results in significant tumor volume reduction and increased apoptotic indices [product_spec, APExBIO; paper, Cancers 2025].
• In assembloid models integrating tumor and stromal subpopulations, drug responsiveness is modulated by the presence of specific stromal cell types, leading to variable sensitivity compared to monocultures [paper, Cancers 2025].
• Oxaliplatin is insoluble in ethanol but achieves ≥3.94 mg/mL solubility in water with gentle warming (37°C), facilitating preparation for cell-based assays [product_spec, APExBIO].
• Oxaliplatin can impair retrograde neuronal transport in animal models, an effect relevant to studies of chemotherapy-induced neurotoxicity [product_spec, APExBIO].

This article extends prior analyses by specifically quantifying protocol parameters and integrating new findings from assembloid research. For in-depth mechanistic coverage, see Oxaliplatin: Platinum-Based Chemotherapeutic Agent for DNA Adduct Studies; this dossier emphasizes validated in vitro/in vivo benchmarks and assembloid translational advances.

Applications, Limits & Misconceptions

Oxaliplatin is widely used in preclinical cancer models, including high-throughput screening for chemotherapy resistance and DNA damage response studies [product_spec]. Its established use in metastatic colorectal cancer therapy (in FOLFOX regimens) is supported by robust clinical and preclinical evidence [paper, Cancers 2025]. Assembloid systems now enable the study of tumor–stroma interactions and resistance mechanisms, addressing previous gaps in conventional 2D/3D models [paper]. However, stromal complexity can reduce apparent drug sensitivity, underlining the need for multi-cellular models in preclinical validation [paper].

Common Pitfalls or Misconceptions

• Misconception: Oxaliplatin efficacy in monocultures directly predicts clinical response. Clarification: Stromal components in assembloids can reduce drug sensitivity [paper, Cancers 2025].
• Pitfall: Assuming high-temperature storage is acceptable. Clarification: Oxaliplatin should be stored at -20°C; solution stability is limited [product_spec].
• Pitfall: Preparing stocks in ethanol. Clarification: The compound is insoluble in ethanol and should be dissolved in water [product_spec].
• Misconception: All neurotoxicity observed in vivo is reversible. Clarification: Oxaliplatin can cause persistent impairment of neuronal transport [product_spec].
• Pitfall: Using the same dose across models. Clarification: Dose optimization is required for each application; general range is 5–10 mg/kg in mice [product_spec].

For a focused review on tumor–stroma modeling, see Oxaliplatin in Tumor-Stroma Co-Culture, which addresses the evolution beyond 2D/3D models—this article updates those insights with assembloid benchmarks.

Workflow Integration & Parameters

Protocol Parameters

• assay: in vitro cytotoxicity | value_with_unit: IC₅₀ 0.1–10 μM (48–72h) | applicability: cancer cell lines (colon, melanoma, ovarian, etc.) | rationale: standard viability benchmarking | source_type: product_spec, APExBIO
• assay: in vivo efficacy | value_with_unit: 5–10 mg/kg (i.p./i.v., q3d, 2–3 wks) | applicability: mouse xenograft models | rationale: tumor volume reduction, apoptosis index | source_type: product_spec, APExBIO
• assay: solubility | value_with_unit: ≥3.94 mg/mL in water (37°C) | applicability: stock preparation for cell assays | rationale: ensures proper dosing | source_type: product_spec, APExBIO
• assay: storage | value_with_unit: -20°C (solid) | applicability: long-term compound stability | rationale: maintains agent integrity | source_type: product_spec, APExBIO
• assay: assembloid drug response | value_with_unit: variable (model-dependent sensitivity) | applicability: 3D assembloid co-culture | rationale: captures stroma-mediated resistance | source_type: paper, Cancers 2025

Protocols may require prewarming and ultrasonic agitation for concentrated stock preparations [product_spec]. For advanced workflow integration, see Oxaliplatin in Translational Oncology; this dossier provides parameterized values and assembloid-specific adaptation.

Conclusion & Outlook

Oxaliplatin remains a benchmark platinum-based chemotherapeutic agent for DNA adduct-driven apoptosis in diverse cancer models. Its validated utility in metastatic colorectal cancer therapy is now being extended through assembloid models that address microenvironmental resistance, as demonstrated in recent research [paper, Cancers 2025]. Limitations include stromal-mediated resistance and neurotoxicity risks. Continuing integration of assembloid and multi-lineage models will further clarify Oxaliplatin’s clinical and research boundaries, improving personalized chemotherapy strategies. All core claims and parameters in this article are supported by peer-reviewed or official product documentation from APExBIO and referenced literature.